arrow
J

J.L. González-Larriba

Hospital Clínico San Carlos
H指数:37
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement

多学科方法治疗早期和局部晚期非小细胞肺癌(NSCLC)患者:西班牙肺癌组(GECP)第二届专家共识声明

2025-09-300
PRE
Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain

肺癌幸存者中第二原发癌的发病率:按肿瘤学治疗的西班牙全国前瞻性队列研究

2025-08-120
OA
PD-L1 expression scoring using artificial intelligence algorithms in non-small cell lung cancer harbouring ROS1 fusions: potential clinical-biological significance

PD-L1表达评分在携带ROS1融合的非小细胞肺癌中采用人工智能算法:潜在的临床-生物学意义

2025-08-110
PRE
KRAS Mutation Status in NSCLC: Distribution across Occupational Categories

KRAS突变状态在非小细胞肺癌中的分布:职业类别的分布

CHEST
IF8.6
2025-07-150
PRE
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study

使用NGS对晚期NSCLC进行全面的分子分型:ATLAS研究中可靶向突变的发生率及临床试验机会

2025-06-010
OAAI
CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment

关键:根据治疗方式分析西班牙胸肿瘤登记处的第二原发癌发生率

2024-09-010
PRE
Early detection of disease progression in NSCLC patients undergoing immunotherapy through ctDNA analysis

通过ctDNA分析早期检测接受免疫治疗的NSCLC患者的疾病进展

2024-09-010
PRE
Phase II, open-label study of frontline tusamitamab ravtansine with pembrolizumab ± chemotherapy in advanced non-squamous non-small cell lung cancer: Updated results from CARMEN-LC05 trial

II期开放标签研究:评估前线tusamitamab ravtansine联合pembrolizumab±化疗治疗晚期非鳞非小细胞肺癌的疗效,CARMEN-LC05试验更新结果

2024-09-012
PRE
Impact of fecal microbiome on the efficacy of neoadjuvant chemo-immunotherapy and colitis adverse events: Findings from the NADIM II Trial
2024-03-220
PRE
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
2023-08-10187
OA
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

肺癌中重要生物标志物的测定: 西班牙人口统计学,临床,流行病学和病理学特征的真实数据研究

2022-07-058
OAAI
Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)
2022-04-010
OAAI
Determination of essential biomarkers in lung cancer: A real-world data study in Spain
2022-04-011
OA
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
2022-01-0158
OAAI
Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)
2021-09-010
OA
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

使用真实数据的长期晚期 (iiib-iv) EGFR突变的非小细胞肺癌 (NSCLC) 幸存者的预后模型

2021-08-318
OAAI